MustGrow Biologics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

MustGrow Biologics (CVE:MGRO) Full Year 2024 Results

Key Financial Results

• Net loss: CA$4.89m (loss widened by CA$4.21m from FY 2023).
• CA$0.095 loss per share (further deteriorated from CA$0.014 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

MustGrow Biologics Earnings Insights

In the last 12 months, the only revenue segment was Agrochemicals contributing CA$398.0k. Notably, cost of sales worth CA$317.5k amounted to 80% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CA$3.35m (67% of total expenses). Explore how MGRO's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 81% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in Canada.

Performance of the Canadian Chemicals industry.

The company's shares are down 3.5% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for MustGrow Biologics you should be aware of, and 1 of them is significant.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.